Metformin for cardiovascular protection, inflammatory bowel disease, osteoporosis, periodontitis, polycystic ovarian syndrome, neurodegeneration, cancer …

M Ala, M Ala - ACS pharmacology & translational science, 2021 - ACS Publications
Diabetes is accompanied by several complications. Higher prevalence of cancers,
cardiovascular diseases, chronic kidney disease (CKD), obesity, osteoporosis, and …

The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases

A Hasanvand - Inflammopharmacology, 2022 - Springer
Metformin can suppress gluconeogenesis and reduce blood sugar by activating adenosine
monophosphate-activated protein kinase (AMPK) and inducing small heterodimer partner …

Elucidation of the Metabolite Profile of Yucca gigantea and Assessment of Its Cytotoxic, Antimicrobial, and Anti-Inflammatory Activities

NGM Attallah, SA El-Sherbeni, AH El-Kadem… - Molecules, 2022 - mdpi.com
The acute inflammation process is explained by numerous hypotheses, including oxidative
stress, enzyme stimulation, and the generation of pro-inflammatory cytokines. The anti …

Interference with the AMPKα/mTOR/NLRP3 signaling and the IL-23/IL-17 axis effectively protects against the dextran sulfate sodium intoxication in rats: a new …

ME Youssef, EE Abd El-Fattah… - Frontiers in …, 2021 - frontiersin.org
Empagliflozin and metformin are widely used for the treatment of type 2 diabetes. These
drugs showed marked anti-inflammatory effects in different animal models via enhancing …

The role of sphingosine-1-phosphate in the gut mucosal microenvironment and inflammatory bowel diseases

F Zou, S Wang, M Xu, Z Wu, F Deng - Frontiers in Physiology, 2023 - frontiersin.org
Sphingosine-1-phosphate (S1P), a type of bioactive sphingolipid, can regulate various
cellular functions of distinct cell types in the human body. S1P is generated intracellularly by …

[HTML][HTML] Therapeutic potential of the sphingosine kinase 1 inhibitor, PF-543

X Yi, X Tang, T Li, L Chen, H He, X Wu, C Xiang… - Biomedicine & …, 2023 - Elsevier
PF-543 is a sphingosine kinase 1 (SPHK1) inhibitor developed by Pfizer and is currently
considered the most potent selective SPHK1 inhibitor. SPHK1 catalyses the production of …

[PDF][PDF] A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease …

SJ Alarfaj, MM Bahaa, HA Yassin… - European Review for …, 2023 - europeanreview.org
OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver metabolic
disease affecting millions globally. This study aimed to assess the safety and efficacy of a …

Combination of metformin and hesperidin mitigates cyclophosphamide-induced hepatotoxicity. Emerging role of PPAR-γ/Nrf-2/NF-κB signaling pathway

KM El-Beheiry, MES El-Sayad, TA El-Masry… - International …, 2023 - Elsevier
Cyclophosphamide (CP) is widely used as an immunosuppressive and chemotherapeutic
drug. However, its therapeutic application is restricted by its adverse effects, particularly …

The role and mechanism of metformin in inflammatory diseases

H Lin, H Ao, G Guo, M Liu - Journal of Inflammation Research, 2023 - Taylor & Francis
Metformin is a classical drug used to treat type 2 diabetes. With the development of research
on metformin, it has been found that metformin also has several advantages aside from its …

The therapeutic effects of cycloastragenol in ulcerative colitis by modulating SphK/MIP‐1α/miR‐143 signalling

A Bagalagel, R Diri, A Noor, D Almasri… - Basic & Clinical …, 2022 - Wiley Online Library
Patients with ulcerative colitis (UC) experience diarrhoea, hematochezia and abdominal
pain. UC is a well‐known health challenge affecting 200–250 per 100 000 individuals …